The regulatory role of STUB1 ubiquitin ligase in interferon-γ receptor stability and its mechanism in tumor immunity

I. Research Background: Interferon-γ Signaling and Tumor Immunotherapy Resistance

Interferon-γ (IFN-γ) is a key effector cytokine secreted by cytotoxic T lymphocytes and natural killer cells, playing multiple roles in antitumor immune responses. It not only enhances the immunogenicity of tumor cells by upregulating major histocompatibility complex (MHC) expression but also directly inhibits tumor cell proliferation and induces apoptosis. However, during immune checkpoint blockade therapy, some tumors evade immune killing by developing intrinsic resistance to IFN-γ signaling, becoming a major cause of treatment failure. Although the downstream signaling pathways of IFN-γ have been extensively studied, how the expression levels of its receptor complex on the cell surface are precisely regulated and how this regulation affects tumor response to immunotherapy remain incompletely understood.

II. Key Discovery: STUB1 as a Critical Negative Regulator of the IFN-γ Receptor Complex

To systematically investigate the molecular mechanisms regulating the cell surface abundance of IFN-γ receptor 1 (IFNGR1), the research team conducted a genome-wide CRISPR/Cas9 loss-of-function screen.

1. Screening and Identification: Through an unbiased screen, the E3 ubiquitin ligase STUB1 was identified as a key negative regulator of IFNGR1 expression. Loss of STUB1 significantly increases the abundance of IFNGR1 on the cell membrane.

2. Mechanistic Analysis: STUB1 does not act in isolation but simultaneously targets two core components of the IFN-γ receptor complex—IFNGR1 and its associated tyrosine kinase JAK1. The study found that STUB1 mediates ubiquitination of IFNGR1 at K285 and JAK1 at K249, leading to degradation of the entire receptor-kinase complex via the proteasome pathway. Notably, these lysine residues are located in the critical structural domains where IFNGR1 and JAK1 interact, suggesting that STUB1 disrupts complex stability to achieve its regulatory function.

III. Research Tool: Application Value of IFN-gamma R1/IFNGR1 Fc Chimera Protein

In studying the interaction mechanisms between IFNGR1 and molecules such as STUB1 and JAK1, standardized and highly functional recombinant proteins are essential tools for validating key hypotheses. The IFN-gamma R1/IFNGR1 Fc Chimera Protein combines functional domains with convenient tags, offering the following research advantages:

1. Retention of Functional Domains: This protein contains the extracellular ligand-binding domain of IFNGR1 fused to the Fc region of human immunoglobulin G1 (IgG1). The Fc region not only enhances protein stability and half-life but also facilitates efficient purification and immobilization via Protein A/G.

2. Interaction Studies: It can serve as a "bait" protein for validating direct binding with STUB1, JAK1, or other potential interacting proteins through surface plasmon resonance, bio-layer interferometry, or pull-down assays, and can be used to assess STUB1-mediated ubiquitination.

3. Antibody and Inhibitor Evaluation: As a standard antigen, it can be used to evaluate the blocking effects of candidate therapeutic antibodies or small-molecule inhibitors on IFNGR1 function.

IV. Biological and Clinical Significance of STUB1 Regulation of IFN-γ Signaling

The STUB1-mediated receptor degradation mechanism has profound implications for tumor cell fate and immunotherapy efficacy.

1. Regulation of Tumor Cell Sensitivity: In vitro experiments showed that STUB1-knockout tumor cells exhibit stronger IFN-γ signaling responses, making them more sensitive to cytotoxic T cell killing.

2. Clinical Relevance: Analysis of tumor samples from patients receiving immune checkpoint inhibitor therapy revealed a significant negative correlation between STUB1 expression levels and IFN-γ pathway activation in tumors, supporting the hypothesis that STUB1 plays an important regulatory role in the human tumor immune microenvironment.

3. Complex Impact on Immunotherapy Response: Animal model experiments further revealed the complexity of its effects. In heterogeneous tumors composed of wild-type and STUB1-deficient tumor cells, anti-PD-1 therapy more effectively eliminated STUB1-deficient cells, showing selective advantage. However, in homogeneous tumors composed entirely of STUB1-deficient cells, the efficacy of anti-PD-1 did not proportionally increase, suggesting that STUB1-regulated IFN-γ signaling has highly context-dependent effects on antitumor immunity, possibly interacting with other immune escape mechanisms.

V. Summary and Future Perspectives

This study systematically reveals for the first time that STUB1, as an E3 ubiquitin ligase, negatively regulates the IFN-γ signaling pathway by simultaneously ubiquitinating and degrading IFNGR1 and JAK1. This discovery not only deepens the understanding of IFN-γ receptor homeostasis regulation but also provides a new molecular perspective for explaining tumor immunotherapy resistance. Molecular interaction studies using tools such as the IFN-gamma R1/IFNGR1 Fc Chimera Protein provide a solid biochemical foundation for this mechanism.

In the future, STUB1 and its mediated ubiquitination may become potential intervention targets for improving tumor immunotherapy responses. However, given the complexity of its effects, follow-up studies need to explore strategies for combining STUB1 inhibition with existing immunotherapies (e.g., immune checkpoint blockade) in models closer to human tumor heterogeneity and precisely define patient populations that could benefit from such combination strategies, ultimately translating basic mechanistic discoveries into clinical therapeutic innovations.

VI. Which Manufacturers Provide IFN-gamma R1/IFNGR1 Fc Chimera Protein?

Nanjing YouAi Protein has independently developed the IFN-gamma R1/IFNGR1 Fc Chimera Protein, Human (Catalog No.: UA011347), a high-purity, high-activity recombinant fusion protein of the human IFN-γ receptor 1 (IFNGR1) extracellular domain. This product is engineered by fusing the extracellular domain of human IFNGR1 with the Fc fragment of human immunoglobulin G (e.g., IgG1) and expressed in mammalian cell systems to form stable homodimers. This product is a key tool for studying IFN-γ signaling pathways, immune regulation, anti-infection immunity, and antibody/drug screening.

Nanjing YouAi Protein is committed to providing high-performance, highly flexible recombinant protein tools for immunology, infection immunity, and antibody drug development. For detailed technical parameters, binding activity (e.g., affinity data with IFN-γ), or application consultation regarding the IFN-gamma R1/IFNGR1 Fc Chimera Protein, Human (Catalog No.: UA011347), please feel free to contact us.